Eicosapentaenoic acid versus docosahexaenoic acid in mild-to-moderate depression: A randomized, double-blind, placebo-controlled trial

European Neuropsychopharmacology

Volumn 23, Issue 7, 2013, Pages 636-644

  Mozaffari Khosravi, Hassan ^a   Yassini Ardakani, Mojtaba ^a   Karamati, Mohsen ^b   Shariati Bafghi, Seyedeh Elaheh ^a  

^a SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adjunctive treatment; Docosahexaenoic acid; Eicosapentaenoic acid; Mild to moderate depression; Randomized controlled trial

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; PLACEBO;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSION; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84878859840     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.08.003     Document Type: Article

References (50)

1. American Psychiatric Association (APA) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) 1994, APA, Washington, DC. 4th ed.
2. Andrade L., Caraveo-Anduaga J.J., Berglund P., Bijl R.V., De Graaf R., Vollebergh W., Dragomirecka E., Kohn R., Keller M., Kessler R.C., Kawakami N., Kilic C., Offord D., Ustun T.B., Wittchen H.U. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) surveys. Int. J. Methods Psychiatr. Res. 2003, 12:3-21.
3. Barbui, C., Hotopf, M., Freemantle, N., Boynton, J., Churchill, R., Eccles, M.P., Geddes, J.R., Hardy, R., Lewis, G., Mason, J.M. Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs). The Cochrane Database of Systematic Reviews 2000, (4). Art. no.: CD002791. http://dx.doi.org/10.1002/14651858.CD002791.
4. Bech P., Cialdella P., Haugh M.C., Birkett M.A., Hours A., Boissel J.P., Tollefson G.D. Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. Br. J. Psychiatry 2000, 176:421-428.
5. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry 1961, 4:561-571.
6. Beller E.M., Gebski V., Keech A.C. Randomisation in clinical trials. Med. J. Aust. 2002, 177:565-567.
7. Bot M., Pouwer F., Assies J., Jansen E.H., Diamant M., Snoek F.J., Beekman A.T., de Jonge P. Eicosapentaenoic acid as an add-on to antidepressant medication for co-morbid major depression in patients with diabetes mellitus: a randomized, double-blind placebo-controlled study. J. Affect. Disord. 2010, 126:282-286.
8. Carney R.M., Freedland K.E., Rubin E.H., Rich M.W., Steinmeyer B.C., Harris W.S. Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. JAMA 2009, 302:1651-1657.
9. Chiu C.C., Su K.P., Cheng T.C., Liu H.C., Chang C.J., Dewey M.E., Stewart R., Huang S.Y. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1538-1544.
10. Cuijpers P., Smit F. Excess mortality in depression: a meta-analysis of community studies. J. Affect. Disord. 2002, 72:227-236.
11. Cuijpers P., Smit F. Subthreshold depression as a risk indicator for major depressive disorder: a systematic review of prospective studies. Acta. Psychiatr. Scand. 2004, 109:325-331.
12. da Silva T.M., Munhoz R.P., Alvarez C., Naliwaiko K., Kiss A., Andreatini R., Ferraz A.C. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J. Affect. Disord. 2008, 111:351-359.
13. Fagiolini A., Kupfer D.J. Is treatment-resistant depression a unique subtype of depression?. Biol. Psychiatry 2003, 53:640-648.
14. Finnen M.J., Lovell C.R. Purification and characterisation of phospholipase A2 from human epidermis. Biochem. Soc. Trans. 1991, 19:91 S.
15. Frangou S., Lewis M., McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br. J. Psychiatry 2006, 188:46-50.
16. Grenyer B.F., Crowe T., Meyer B., Owen A.J., Grigonis-Deane E.M., Caputi P., Howe P.R. Fish oil supplementation in the treatment of major depression: a randomised double-blind placebo-controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1393-1396.
17. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
18. Hibbeln J.R. Fish consumption and major depression. Lancet 1998, 351:1213.
19. Hibbeln J.R., Salem N. Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. Am. J. Clin. Nutr. 1995, 62:1-9.
20. Jazayeri S., Tehrani-Doost M., Keshavarz S.A., Hosseini M., Djazayery A., Amini H., Jalali M., Peet M. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust. N. Z. J. Psychiatry 2008, 42:192-198.
21. Judd L.L., Schettler P.J., Akiskal H.S. The prevalence, clinical relevance, and public health significance of subthreshold depressions. Psychiatr. Clin. North Am. 2002, 25:685-698.
22. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., Rush A.J., Walters E.E., Wang P.S. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.
23. Lam R.W., Levitan R.D. Pathophysiology of seasonal affective disorder: a review. J. Psychiatry Neurosci. 2000, 25:469-480.
24. Leonardi F., Attorri L., Benedetto R.D., Biase A.D., Sanchez M., Tregno F.P., Nardini M., Salvati S. Docosahexaenoic acid supplementation induces dose and time dependent oxidative changes in C6 glioma cells. Free Radic. Res. 2007, 41:748-756.
25. Leonardi F., Attorri L., Di Benedetto R., Di Biase A., Sanchez M., Nardini M., Salvati S. Effect of arachidonic, eicosapentaenoic and docosahexaenoic acids on the oxidative status of C6 glioma cells. Free Radic. Res. 2005, 39:865-874.
26. Lonergan P.E., Martin D.S., Horrobin D.F., Lynch M.A. Neuroprotective actions of eicosapentaenoic acid on lipopolysaccharide-induced dysfunction in rat hippocampus. J. Neurochem. 2004, 91:20-29.
27. Lucas M., Asselin G., Merette C., Poulin M.J., Dodin S. Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Am. J. Clin. Nutr. 2009, 89:641-651.
28. Lynch A.M., Loane D.J., Minogue A.M., Clarke R.M., Kilroy D., Nally R.E., Roche O.J., O'Connell F., Lynch M.A. Eicosapentaenoic acid confers neuroprotection in the amyloid-beta challenged aged hippocampus. Neurobiol. Aging 2007, 28:845-855.
29. Marangell L.B., Martinez J.M., Zboyan H.A., Kertz B., Kim H.F., Puryear L.J. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am. J. Psychiatry 2003, 160:996-998.
30. Martins J.G. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J. Am. Coll. Nutr. 2009, 28:525-542.
31. Minogue A.M., Lynch A.M., Loane D.J., Herron C.E., Lynch M.A. Modulation of amyloid-beta-induced and age-associated changes in rat hippocampus by eicosapentaenoic acid. J. Neurochem. 2007, 103:914-926.
32. Mischoulon D., Best-Popescu C., Laposata M., Merens W., Murakami J.L., Wu S.L., Papakostas G.I., Dording C.M., Sonawalla S.B., Nierenberg A.A., Alpert J.E., Fava M. A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. Eur. Neuropsychopharmacol. 2008, 18:639-645.
33. Mischoulon D., Papakostas G.I., Dording C.M., Farabaugh A.H., Sonawalla S.B., Agoston A.M., Smith J., Beaumont E.C., Dahan L.E., Alpert J.E., Nierenberg A.A., Fava M. A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J. Clin. Psychiatry 2009, 70:1636-1644.
34. Nemets B., Stahl Z., Belmaker R.H. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am. J. Psychiatry 2002, 159:477-479.
35. Ohishi K., Ueno R., Nishino S., Sakai T., Hayaishi O. Increased level of salivary prostaglandins in patients with major depression. Biol. Psychiatry 1988, 23:326-334.
36. Peet M., Horrobin D.F. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch. Gen. Psychiatry 2002, 59:913-919.
37. Piccirillo G., Fimognari F.L., Infantino V., Monteleone G., Fimognari G.B., Falletti D., Marigliano V. High plasma concentrations of cortisol and thromboxane B2 in patients with depression. Am. J. Med. Sci. 1994, 307:228-232.
38. Rogers P.J., Appleton K.M., Kessler D., Peters T.J., Gunnell D., Hayward R.C., Heatherley S.V., Christian L.M., McNaughton S.A., Ness A.R. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br. J. Nutr. 2008, 99:421-431.
39. Rondanelli M., Giacosa A., Opizzi A., Pelucchi C., La Vecchia C., Montorfano G., Negroni M., Berra B., Politi P., Rizzo A.M. Effect of omega-3 fatty acids supplementation on depressive symptoms and on health-related quality of life in the treatment of elderly women with depression: a double-blind, placebo-controlled, randomized clinical trial. J. Am. Coll. Nutr. 2010, 29:55-64.
40. Rugulies R. Depression as a predictor for coronary heart disease. a review and meta-analysis. Am. J. Prev. Med. 2002, 23:51-61.
41. Sadeghirad B., Haghdoost A.A., Amin-Esmaeili M., Ananloo E.S., Ghaeli P., Rahimi-Movaghar A., Talebian E., Pourkhandani A., Noorbala A.A., Barooti E. Epidemiology of major depressive disorder in iran: a systematic review and meta-analysis. Int. J. Prev. Med. 2010, 1:81-91.
42. Silvers K.M., Woolley C.C., Hamilton F.C., Watts P.M., Watson R.A. Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot. Essent. Fatty Acids 2005, 72:211-218.
43. Simopoulos A.P. Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr. 2002, 21:495-505.
44. Sohn C.H., Lam R.W. Update on the biology of seasonal affective disorder. CNS Spectr. 2005, 10:635-646. (quiz 631-614).
45. Sontrop J., Campbell M.K. Omega-3 polyunsaturated fatty acids and depression: a review of the evidence and a methodological critique. Prev. Med. 2006, 42:4-13.
46. Su K.P., Huang S.Y., Chiu C.C., Shen W.W. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur. Neuropsychopharmacol. 2003, 13:267-271.
47. Sublette M.E., Ellis S.P., Geant A.L., Mann J.J. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J. Clin. Psychiatry 2011, 72:1577-1584.
48. Tajalizadekhoob Y., Sharifi F., Fakhrzadeh H., Mirarefin M., Ghaderpanahi M., Badamchizade Z., Azimipour S. The effect of low-dose omega 3 fatty acids on the treatment of mild to moderate depression in the elderly: a double-blind, randomized, placebo-controlled study. Eur. Arch. Psychiatry Clin. Neurosci. 2011, 261:539-549.
49. Vieweg W.V., Hasnain M., Lesnefsky E.J., Pandurangi A.K. Review of major measuring instruments in comorbid depression and coronary heart disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:905-912.
50. Yang D.Y., Pan H.C., Yen Y.J., Wang C.C., Chuang Y.H., Chen S.Y., Lin S.Y., Liao S.L., Raung S.L., Wu C.W., Chou M.C., Chiang A.N., Chen C.J. Detrimental effects of post-treatment with fatty acids on brain injury in ischemic rats. Neurotoxicology 2007, 28:1220-1229.